New Flucloxacillin Stability Data Supports Flexible OPAT Delivery with Accufuser®
Outpatient Parenteral Antimicrobial Therapy services require confidence that medicines remain stable not only during infusion, but across the full preparation, transport and in‑use workflow. New independent stability data now provides additional reassurance for the use of Flucloxacillin within established OPAT pathways using Accufuser® elastomeric infusion devices.
An independent study conducted by Biopharma Stability Testing Laboratory (BSTL) assessed the stability of Flucloxacillin prepared at clinically relevant concentrations of 10 mg/mL and 50 mg/mL in Accufuser® devices. The testing was designed to reflect real‑world OPAT practice, including preparation, transport and extended in‑use conditions.
Demonstrated Stability Across the OPAT Workflow
The study confirmed that Flucloxacillin reconstituted and diluted in 0.9% saline remained within UK NHS Yellow Cover Document acceptance limits throughout a 24‑hour OPAT workflow.
Stability was maintained following up to 2 hours of preparation and transport at 25°C, followed by 24 hours in use at a controlled temperature of 25°C. This provides reassurance that Flucloxacillin can be safely delivered over a full day when administered via Accufuser®, supporting once‑daily dosing in the community.
In addition to chemical stability, product quality was assessed throughout testing. All samples remained clear, colourless and free from visible particles, with sub‑visible particle levels returning to within British Pharmacopoeia and European Pharmacopoeia limits by the end of the storage period.
Supporting Service Continuity and Choice
Alongside previously published data demonstrating extended stability of Flucloxacillin when prepared using buffered diluents and stored under refrigerated conditions, these new findings provide OPAT services with additional flexibility in how Flucloxacillin is prepared and delivered.
The confirmation of suitability in 0.9% saline is particularly relevant during periods when citrate‑buffered saline may be unavailable, helping services maintain continuity of care while remaining compliant with recognised UK standards.
Combined with Accufuser’s proven performance in ambulatory infusion, this evidence supports confident use of Flucloxacillin across a range of OPAT settings.
For further information on Accufuser® or support implementing this data within your OPAT pathway, please contact your Vygon Product Specialist.